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Mesenchymal stromal cells (MSC) present in the tumor microenvironment [usually 
named tumor-associated fibroblasts (TAF)] can exert immunosuppressive effects on 
T and natural killer (NK) lymphocytes, favoring tumor immune escape. We have analyzed 
this mechanism in colorectal carcinoma (CRC) and found that co-culture of NK cells with 
TAF can prevent the IL-2-mediated NKG2D upregulation. This leads to the impairment 
of NKG2D-mediated recognition of CRC cells, sparing the NK cell activation through 
DNAM1 or FcγRIIIA (CD16). In situ, TAF express detectable levels of epidermal growth 
factor receptor (EGFR); thus, the therapeutic anti-EGFR humanized antibody cetuximab 
can trigger the antibody-dependent cellular cytotoxicity of TAF, through the engage-
ment of FcγRIIIA on NK cells. Importantly, in the tumor, we found a lymphoid infiltrate 
containing NKp46+CD3− NK  cells, enriched in CD16+ cells. This population, sorted 
and cultured with IL-2, could be triggered via CD16 and via NKG2D. Of note, ex vivo 
NKp46+CD3− cells were able to kill autologous TAF; in vivo, this might represent a control 
mechanism to reduce TAF-mediated regulatory effect on NK cell function. Altogether, 
these findings suggest that MSC from the neoplastic mucosa (TAF) of CRC patients can 
downregulate the immune cell recognition of CRC tumor cells. This immunosuppression 
can be relieved by the anti-EGFR antibody used in CRC immunotherapy.
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inTrODUcTiOn
Several reports have shown that mesenchymal stromal cells (MSC) can exert potent immunosup-
pressive effects leading to the downregulation of T and natural killer (NK) cell responses; indeed, 
the interaction between MSC isolated from bone marrow and effector lymphocytes can lead to the 
suppression of T cell proliferation and NK cell cytotoxic activity (1–7). In addition, MSC-mediated 
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immunosuppression has been reported to favor tumor growth in 
animal models (8). These cells are represented in the tumor micro-
environment as tumor-associated fibroblasts (TAF), myofi broblasts, 
pericytes, adipocytes, lymphatic, and vascular endothelial cells 
(9, 10). All these cell types can influence the antitumor immune 
response and the fate of tumor cells (9–12). In normal gut, MSC 
are a major structural component of crypts, constituting the peri-
cryptal fibroblast sheath (13). The intestinal crypt is a prolifera-
tive compartment maintained by stem cells and some evidences 
support that colorectal carcinoma (CRC) can emerge at the niche 
of tissue stem cells (14). Thus, MSC can play a role in regulating 
epithelial cell proliferation and differentiation (13–15); more 
importantly, some reports have indicated MSC as an attractive 
target for antitumor vaccine (16–19). Recently, it has been shown 
in a murine model that targeting TAF and tumor cells is effec-
tive in modifying tumor microenvironment. Indeed, the use of 
tumor cells expressing fibroblast activation protein as a vaccine 
resulted in the elimination of solid tumor and impairment of vas-
cular dissemination. Importantly, this effect was accompanied by 
tumor infiltration of CD8+ T cells, reduction of TAF number and 
inhibition of the recruitment of immunosuppressive cells within 
the tumor (16–19). Based on these considerations, it is relevant 
to determine whether MSC derived from CRC mucosa display 
immunosuppressive properties. Indeed, it has been shown that 
TAF in melanoma patients may exert potent inhibiting effects 
on NK  cell responses (20). In addition, TAF from head and 
neck cancer can inhibit T cell proliferation, further suggesting 
that mesenchymal cells can regulate the antitumor immune 
response (21). These findings indicate that also in humans MSC 
can be a suitable target for cancer therapies aimed to revert 
their immunosuppressive effect and allow the development of 
NK cell-mediated antitumor response (9). NK cells can bind to 
tumor targets through the interaction of lymphocyte function 
associated (LFA)1 and intercellular adhesion molecule (ICAM)1 
expressed on tumor cells (22). This interaction leads to the 
engagement of NK cell activating receptors, including NKG2D 
or DNAM1 (23, 24), which bind to their ligands on tumor cells 
triggering their killing (23–25). In particular, CRC cells can 
express the NKG2D ligands (NKG2D-L) MICA and ULBPs, or 
the DNAM1 ligands (DNAM1-L) poliovirus receptor (PVR) and 
nectin-2: NKG2D–NKG2D-L and DNAM1–DNAM1-L interac-
tion would lead to CRC cell recognition and killing by NK effec-
tor cells (26). NK cells can kill tumor cells also by the triggering 
of antibody-dependent cellular cytotoxicity (ADCC) through the 
engagement of FcγRIIIA (CD16) (27). This mechanism has been 
exploited in anti-cancer immunotherapy with the anti-epidermal 
growth factor receptor (EGFR) antibody cetuximab in KRAS 
wild type CRC (27, 28). Thus, the presence of functional NK cells 
can contribute both to CRC cell control and to the success of 
immunotherapy.
In this work, we show that: (1) TAF downregulate the NKG2D-
mediated killing of CRC and prevent the IL-2 induced NKG2D 
upregulation on NK  cells. (2) TAF express EGFR and can be 
killed by NK cells in ADCC triggered via the anti-EGFR antibody 
cetuximab. (3) NKp46+CD3− NK cells found at the tumor site, 
sorted and cultured with IL-2, can kill autologous TAF.
MaTerials anD MeThODs
Monoclonal antibodies (mabs)  
and reagents
Anti-NKG2D (MAB139, IgG1), anti-DNAM1 (MAB666, IgG1), 
anti-CD32 (MAB1330, IgG2a), anti-CD64 (FAP12571, IgG1), anti- 
CD56 (301040, IgG2b), anti-CD90 (FAB2067p, IgG2a), anti-PVR 
(MAB25301, IgG1), anti-ULBP1 (MAB1380, IgG2a), ULBP2 
(MAB1298, IgG2a), ULBP3 (MAB15171, IgG2a), and anti-
CD146 (MAB932, IgG1) mAbs were purchased from R&D System 
(Minneapolis, MN, USA). The anti-CD3 mAb (JT3A, IgG2a), the 
anti-CD16 mAbs (NK1, IgG1 and NK54, IgG2a), the anti-CD18 
mAb (70H12, IgG2a), the anti-CD54 mAb (ICAM1, clone SM89, 
IgM), the anti-MICA (M320, IgM), and the anti-CD45 (T205, 
IgM) were obtained in our laboratory (4). The PE-anti-NKp46 
(9E2, IgG1) was purchased from Miltenyi biotech (Germany, EU); 
Alexafluor488-anti-CD45 (HI30, IgG1), PE-Cy7-anti-NKp46 
(9E2, IgG1), PE/Dazzle-anti-CD3 (UCHT1, IgG1), PE-Cy5 anti-
CD56, Pacific Blue-anti-CD16, and anti-NKG2A (16A11, IgG2b) 
mAbs were from BioLegend (San Diego, CA, USA). The anti-SH2 
(CD105, IgG1), the anti-SH3 (CD73, IgG2b), the anti-CD11a 
(LFA1α, TS1.22, IgG1), and the anti-CD18 (LFA1β, TS1.18, IgG1) 
producing hybridomas were purchased from the American Type 
Culture Collection (Manassas, VA, USA). Anti-vimentin mAb 
was from Dako Cytomation (clone V9) and anti-collagen I was 
from Novus Biologicals LLC (Littelton, CO, USA, clone NB600-
450). The therapeutic anti-EGFR cetuximab and anti-CD20 
rituximab humanized antibodies were from the Antiblastic Drug 
Unit of the Policlinico San Martino (Genoa, Italy) as the leftover 
of the dose delivered to patients for immunotherapy. Complete 
medium was composed of RPMI1640 (Thermo Fisher Scientific, 
Carlsbad, CA, USA) with 10% of fetal calf serum (FCS, Sigma) 
supplemented with 1% antibiotics (penicillin and streptomycin) 
and 1% l-glutamine (Thermo Fisher Scientific).
crc cell lines and cell isolation From 
Tumor specimens
CRC cell lines Caco2, HT29, HCT15, SW480, DLD1, HCT116, 
LS180, WiDr, LoVo, Colo205, Colo320 DMF, SW620, T84, and 
SW48 were from cell bank of the IRCCS (kind gift of Blood 
Transfusion Centre, Dr. Barbara Parodi), and for the three CRC 
cell lines used in cytolytic assays (Caco2, HCT15, and SW480), 
the correct identification was determined with STR DNA profile. 
Peripheral blood mononuclear cells (PBMC) were obtained from 
venous blood samples of healthy donors of the Transfusional 
Centre of the Policlinico San Martino (upon signed institutional 
informed consent, according to a procedure defined by the 
Regional Ethic Committee, CONSAZH780148/17/07/2015) 
after Ficoll-Hypaque density gradient separation (29). NK cells 
from PBMC, or from tumor tissue suspensions (see below), were 
obtained using the corresponding RosetteSep negative separation 
kit (StemCell Technologies SARL, Grenoble, France). The purity 
of NK  cell populations ranged from 75 to 95% for the expres-
sion of CD56, 65 to 85% CD16+, and >99.8% of CD3− cells. 
The CD3− but CD56− and CD16− cells were CD20+CD19+ B cells 
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(5–15%). CRC specimens were obtained from the Surgical 
Oncology Unit during therapeutic surgery after signed informed 
consent (Institutional and Regional Ethic Committee approval, 
PR163REG2014). Characterization of NK phenotype in cell sus-
pensions, obtained as described (30), from tumor specimens or 
macroscopically tumor free mucosa counterpart, was performed 
by FACS analysis. In some experiments, NK cells were separated 
from tumor cell suspensions (n = 5), by FACS sorting (FACSAria 
II, BD Biosciences, San Josè, CA, USA) after double staining 
with PE-Cy7-anti-NKp46 and PE/Dazzle-anti-CD3 mAbs. 
Purity of cell sorting was 98.5% (two anti-CD3 mAbs, JT3A and 
UCHT1, were used to define the purity of the bulk population as 
CD3− NK cells). Cells were then put in culture in RPMI1640 sup-
plemented with 10% FCS and 10 ng/ml IL-2 (30 IU/ml, Miltenyi 
Biotech GmbH, Bergisch, Gadbach, Germany, specific activity 
3 ×  106IU) on irradiated PBMC as feeder cells in U-bottomed 
plates. Cell cultures were then split when evident cell growth was 
microscopically detected, checked for the expression of NKP46 
on day 25 (>90%) and used in functional assays. Generation 
of primary MSC lines was obtained after mincing of both CRC 
mucosa (TAF) and normal appearing mucosa, sampled at least 
10 cm from the tumor [fibroblasts (FB)], and enzyme digestion as 
previously reported (31). Cell suspensions were seeded in culture 
wells and after 36 h non-adherent cells were removed. Adherent 
cells showing a fibroblast-like morphology were cultured for 
additional 7 day. At confluence, cell cultures were split and 
expanded as described (32). Phenotype for the indicated markers 
was analyzed at different time points and the expression of these 
markers was similar along the culture period of 2 months. Thus, 
MSC/TAF or MSC/FB expressed CD73, CD90, CD105, CD146, 
collagen I, vimentin (Figure S1 in Supplementary Material), 
bone sialoprotein, CD44, CD29, class I human leukocyte antigen 
(HLA-I), prolyl-4-hydroxylase, alkaline phoshatase, fibroblast 
activation protein, smooth muscle actin, the transcription marker 
SOX-2, and osteopontin but not CD45, CD31, CD33, CD34, CD3, 
CD2, CD16, CD14, ICAM2, ICAM3, CD80, CD86, CD83, and 
HLA-DR (31, 32). Nanog, OCT3-4 SSE-4, and TRA-1-60 stem 
cell markers were negative in both types of MSC (not shown).
cytotoxicity assay
Cytolytic assay was performed as described previously (32, 33). 
Target cells were colon mucosa-derived MSC (TAF or FB) or the 
CRC cell lines Caco2, HCT15, and SW480. All these targets were 
cultured in RPMI 1640 24 h prior to the cytolytic assay and used in 
cytotoxicity experiments at the effector:target (E:T) ratio of 20:1. 
Reverse cytotoxicity was performed using the anti-NKG2D, the 
anti-DNAM1, the anti-CD16, the anti-NKp46, the anti-CD3, or 
the anti-CD56 mAbs, all at 2 µg/ml, and the FcγR positive murine 
P815 cell line [antibody-triggered cellular cytotoxicity (ATCC)], 
as described (33, 34) at 5:1 E:T ratio. Cells were labeled with 
51Cr, washed, and seeded with effector cells. 51Cr-specific release 
was calculated as: experimental release (counts) − spontaneous 
release (counts)/maximum release (counts) − spontaneous release 
(counts). Maximum and spontaneous release were calculated as 
described (33, 34). In some experiments, saturating amounts of 
mAbs to NKG2D or DNAM1 or LFA1 and ICAM1 (2 µg/ml) were 
added. Target cells were also tested for their reactivity with the Fc 
chimeras (soluble receptors fused with the Fc of human immuno-
globulins) NKG2D-Fc, DNAM1-Fc, NKp30-Fc, NKp44-Fc, and 
NKp46-Fc (R&D System), to determine the expression of ligands 
for these NK  cell-activating receptors. NKp30-Fc, NKp44-Fc, 
and NKp46-Fc did not react with target cells (not shown). The 
expression of NKG2D-L and DNAM1-L on target cells was 
further confirmed with specific antibodies to MICA and ULBP3 
(NKG2D-L) or CD115 (poliovirus receptor, PVR, as DNAM1-L) 
by immunofluorescence and FACS analysis (Figures S2 and S3 in 
Supplementary Material). In ADCC, the anti-EGFR cetuximab 
or the anti-CD20 rituximab humanized antibody (2 µg/ml) were 
added at the onset of the cytolytic assay, performed at the E:T ratio 
of 5:1. In another series of experiments, sorted NKp46+CD3− cells 
were expanded in IL-2-containing medium and used either in 
ATCC as above or in cytotoxicity assay against HLA-I+ Caco2 or 
HLA-I− HCT15 CRC cell line in a 51Cr release assay, or against 
autologous TAF: in this case, the crystal violet viability assay was 
used to evaluate target cell damage (35).
immunofluorescence and cytofluorimetric 
analysis
Immunofluorescence on either lymphocytes or colon MSC or 
CRC cell lines was performed with the indicated fluorophore-
conjugated mAbs or primary mAbs followed by the addition of 
anti-isotype-specific goat anti-mouse (GAM) antisera (Southern 
Biotechnology, CA, USA) conjugated with AlexaFluor647 
(Invitrogen, Thermo Fisher Scientific) as indicated. Control samples 
were stained with fluorophore-conjugated isotype control mAbs or 
isotype-matched irrelevant mAb (Becton Dickinson, Paolo Alto, 
CA, USA) followed by anti-isotype specific GAM-AlexaFluor647. 
To assess the reactivity of Fc chimeras, cetuximab or rituximab 
an anti-human immunoglobulin antiserum conjugated with 
AlexaFluor647 was used (Thermo Fisher Scientific). Samples 
were run on a CyAn ADP cytofluorimeter (Beckman-Coulter, 
Pasadena, CA, USA), analyzed with the Summit computer pro-
gram (Beckman-Coulter), and are expressed as Log fluorescence 
intensity vs number of cells.
co-cultures of colon TaF, FB,  
and nK cells
2  ×  104/sample MSC were co-cultured with NK  cells at the 
NK:MSC ratio of 5:1 in 96W-microwell flat-bottomed plates 
(this was the first NK:MSC ratio at which an evident inhibition 
of NKG2D upregulation was detected; this ratio was determined 
in preliminary titration experiment starting from NK:MSC ratio 
of 20:1, 10:1, 5:1, 2:1, and 1:1) with 10 ng/ml IL-2 for 6 days and 
then analyzed for the expression and function of NKG2D and 
DNAM1 activating receptors by immunofluorescence and reverse 
cytotoxicity [or antibody-triggered cellular cytotoxicity (ATCC)]. 
In some experiments, NK cells were seeded on Millicell transwell 
(TW) with 0.3 µm pores (Millipore Corporation, Billerica, MA, 
USA) put into 24w plates with TAF or FB (6 × 104/sample, the 
same number/area of culture well used for co-cultures of NK cells 
in direct contact with MSC) seeded in the lower chamber of the 
well, to avoid the contact with NK cells. Supernatants (SN) were 
collected from TAF cultures after 48 h for transforming growth 
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factor (TGF)β measurement by ELISA (eBioscences, Thermo 
Fischer Scientific), after treatment for 10  min of each SN with 
1N HCl as described (36). Results were normalized to a standard 
curve and expressed as picogram per milliliter.
immunohistochemistry
Paraffin-embedded samples from six CRC patients were analyzed. 
Immunohistochemistry was performed on 6-μm-thin sections, 
deparaffinized in xylene, and treated with Peroxo-Block (Thermo 
Fisher Scientific) to quench endogenous peroxidase, followed by 
Ultra V Block reagent (Ultravision Detection System, BioOptica, 
Thermo Fisher Scientific). Cetuximab and rituximab humanized 
antibodies were biotinylated using EZ-Link Sulfo-NHS-LC-
Biotin (Thermo Fisher Scientific), according to the manufac-
turer’s instruction. These reagents were then added overnight to 
the slides, compared to the anti-vimentin mAb or to an isotypic 
unrelated antibody used as negative control (Dako Cytomation, 
Milan, Italy). Slides were then washed and incubated for 30 min 
with HRP-conjugated streptavidin (Thermo Fisher Scientific) 
and the reaction was developed using 3,3′-diaminobenzidine 
as chromogen. Subsequently, slides were counterstained with 
hematoxylin, cover-slipped with Eukitt (Bioptica, Thermo Fisher 
Scientific), and analyzed under an Leica DM MB2 microscope 
(Wetzlar, Germany) equipped with a charged coupled device 
camera (Olympus DP70, Tokyo, Japan) with a 20× or 40× objective.
cDna reverse Transcription and 
Quantitative real-Time Pcr (Q-rT-Pcr)
Natural killer cells cultured with IL-2 and colon MSC at the 
NK:MSC ratio of 5:1 were harvested at different time points (0, 3, 
6, and 24 h) and analyzed for the expression of NKG2D receptor 
mRNA by Q-RT-PCR, as described (35). RNA was extracted with 
TriPure (Roche Diagnostic, Milan, Italy) and cDNA synthesis was 
performed with random primers. To verify quantitative Q-RT-
PCR efficiency, decreasing amounts (50, 10, and 0.1 ng) of normal 
RNA were used for CT titration. Primers and probes for NKG2D 
were purchased by Applied Biosystem (Hs00183683_m1, Thermo 
Fisher Scientific). Q-RT-PCR was performed on the 7900HT 
FastRT-PCR system with the fluorescent Taqman method and 
normalized to 18s (Hs9999901_s1, Thermo Fisher Scientific). 
After subtracting the threshold cycle (CT) value for 18s from the 
CT values of target genes, results were expressed as 2−ΔΔCT expres-
sion ratio following MIQE guidelines.
statistical analysis
Data were analyzed by applying the two-tailed Student’s t test at 
99% confidence, or the non-parametric two-tailed t test (Mann–
Whitney), using the GraphPad Prism software (La Jolla, CA, USA).
resUlTs
TaF isolated From crc inhibit nK cell 
antitumor activity
We first analyzed the phenotype of MSC isolated from the tumor 
(TAF) and from tumor free mucosa (FB). We found that TAF 
and FB expressed CD73, CD90, CD105, and CD146, collagen I or 
vimentin and ICAM1 (Figures S1A,B in Supplementary Material, 
one representative case and Figures S1C,D in Supplementary 
Material, mean of six different cases). Moreover, TAF and FB 
reacted with the NKG2D and DNAM1 receptors when used 
as chimeric molecules and with antibodies to the NKG2D-L 
(MICA and ULBP3) and the DNAM1-L (PVR) (Figures S1B,D in 
Supplementary Material). Then, we analyzed whether co-culture 
of NK  cells with CRC-derived MSC could affect the killing of 
established CRC cell lines.
Among a panel of 14 cell lines (see Materials and Methods), all 
reacting with Fc-DNAM1 chimera and all but T84 and Colo205 
cell lines, with Fc-NKG2D chimera (Figure S2 in Supplementary 
Material) we chose the three representative CRC cell lines Caco2, 
HCT15, and SW480 expressing the adhesion molecule ICAM1 
(Figure S2 in Supplementary Material) and the ligands of NKG2D 
(MICA and ULBPs) and DNAM1 activating receptors (PVR, 
Figure S3 in Supplementary Material). Moreover, Caco2 was 
selected as it does not display any mutation of KRAS, BRAF, and 
PI3K genes, while HCT15 and SW480 are mutated for KRAS 
(28). The Fc-NKp30, Fc-NKp44, and Fc-NKp46 chimeras did not 
react with the three analyzed CRC cell lines (not shown).
We found that IL-2-activated NK  cells derived from co-
cultures with tumor-derived MSC (NK/TAF) exerted lower 
cytotoxicity of Caco2, HCT15, and SW480 CRC cell lines, com-
pared to NK cells cultured with IL-2 alone that were efficiently 
able to lyse CRC (Figures 1A–C, NK/TAF vs NK in each panel). 
NKG2D, DNAM1, and LFA1 molecules were all involved in 
CRC recognition and killing; indeed, the addition of mAbs 
against these molecules efficiently reduced target cell lysis and 
the simultaneous covering of all these receptors almost abol-
ished NK cell mediated cytotoxicity (Figures 1A–C). Of note, 
the anti-NKG2D mAb did not inhibit tumor cell lysis exerted 
by NK/TAF cells (Figures 1A–C, dark vs light gray), suggest-
ing that NKG2D-mediated recognition is impaired, at variance 
with anti-DNAM1 or anti-LFA1 mAbs (Figures 1A–C, white 
whiskers). These results indicate that CRC cells are recognized 
and killed by NK cells through the interaction of LFA1, NKG2D, 
and DNAM1 with their ligands expressed on target cells; fur-
ther, TAF can affect NK cell mediated lysis of CRC cell lines, 
mainly interfering on the function of NKG2D. Noteworthily, 
NK  cells harvested from NK/TAF co-cultures, could still be 
triggered by cetuximab, even at a very low E:T ratio (5:1), 
and exert ADCC against Caco2, HCT15, and SW480 cell lines 
(Figures 1D–F).
It is of interest that the surface expression of NKG2D was 
markedly reduced in NK cells recovered from co-cultures with 
TAF (NK/TAF, Figure  2A, one representative experiment and 
Figure 2B, mean of six experiments with six different TAF); this 
decrease was not evident when NK and MSC were co-incubated 
for the same time but separated by a transwell system (NK TW/
TAF, Figures 2A,B). No effect on CD16 (Figure 2A) or DNAM1 
or LFA1 (not shown) expression was observed. Of note, co-incu-
bation with TAF inhibited in NK cells the upregulation of mRNA 
coding for NKG2D triggered by IL-2 (Figure 2C); this finding 
suggests that the downregulation of NKG2D surface expression 
A B C
D E F
FigUre 1 | Natural killer (NK) cell killing of CRC lines is inhibited by tumor-associated fibroblasts (TAF). The carcinoma cell line Caco2 (a), HCT15 (B), and SW480 
(c) were analyzed for their sensitivity to IL-2-activated NK cell mediated lysis [effector:target (E:T) ratio 20:1] without (light gray whiskers) or with monoclonal 
antibodies to NKG2D (dark gray whiskers) or DNAM1 or lymphocyte function associated (LFA)1 (2 µg/ml), alone or in combination. (D–F) NK cell activity (E:T ratio 
5:1) against Caco2 (D), HCT15 (e), and SW480 (F) in the absence or in the presence of cetuximab or rituximab (2 µg/ml). NK cells were either cultured alone (NK) 
or derived from co-cultures with mesenchymal stromal cells from CRC mucosa (NK/TAF). Results are shown as percentage of 51Cr-specific release and they are the 
mean with boxes and whiskers min to max of six experiments with NK cells derived from six distinct co-cultures with TAF. In each panel: ***p < 0.0001; **p < 0.001; 
ns, not significant.
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is mainly due to the impairment of the IL-2 mediated upregula-
tion of mRNA for NKG2D and consequent reduced synthesis of 
NKG2D protein. More importantly, TGFβ, a cytokine involved 
in the downregulation of NKG2D protein expression (34) was 
detected in the SN of cultured TAF from six different patients 
(Figure  2D). In turn, specific inhibitors of prostaglandin (PG)
E2 synthesis or indoleamine dioxigenase activity did not affect 
the TAF-mediated reduction of NKG2D expression (not shown). 
Finally, we observed that NK cells co-cultured with TAF showed a 
markedly lower cytolytic activity triggered by the NKG2D recep-
tor in reverse killing (ATCC) against the P815 cell line, compared 
to that of NK cells cultured without TAF (Figure 2E). In this assay, 
cytolytic activity is due to the activation on the effector NK cell 
of a receptor recognized by a specific mAb that, in turn, binds to 
the Fc receptor of P815 cells acting as a bridge between effector 
and target. It is of note that triggering of NK cells through the 
CD16 receptor was very strong and similar in NK cells recovered 
from co-cultures with TAF to that displayed by NK cells alone 
(Figure 2E).
crc-Derived TaF express egFr and can 
Be Targeted by the anti-egFr humanized 
antibody cetuximab
As TAF/NK cross talk does not interfere with CD16-triggered 
NK cytotoxicity, we analyzed if the EGFR humanized anti-
body cetuximab can recognize MSC and lead to their killing. 
We have described that CRC-derived TAF primary cultures 
express EGFR (35): here, we confirmed that cetuximab can 
bind EGFR on these cells, either TAF or FB (Figure 3A shows 
one representative experiment out of six cases showing >90% 
positive cells with a MFI range of 65–130, not shown). Of 
note, we found that cetuximab reacted with TAF (identified by 
vimentin staining, Figures  4D,I,P) at the tumor site in CRC 
(Figure 4B, enlarged in Figure 4C) and stained also FB in non-
neoplastic areas (Figure 4G, enlarged in Figure 4H). Epithelial 
cells expressed EGFR as well (Figures  4N,O). The specificity 
of cetuximab reaction with TAF in tumor specimens was also 
supported by the finding that the isotype-matched antibody 
A B
C D E
FigUre 2 | Tumor-associated fibroblasts (TAF) regulate the expression and function of NKG2D on activated natural killer (NK) cells. (a) NK cells were cultured with 
IL-2 for 6 days in contact with TAF (NK/TAF), or in the upper chamber of a transwell plate containing TAF in the lower chamber (NK TW/TAF), and analyzed for the 
expression of NKG2D (upper row, gray histogram) or CD16 (lower row, gray histogram) by immunofluorescence with the specific monoclonal antibodies (mAbs) 
followed by Alexafluor647 anti-isotype antiserum and FACS analysis. White histograms: cells labeled with the anti-isotype antiserum alone. NK alone (NK) or cultured 
in the transwell (NK TW) and freshly isolated (resting) NK were analyzed as controls. In each subpanel: percentage and the mean fluorescence intensity (MFI, a.u.)  
of positive cells. Results are expressed as Log far-red fluorescence intensity vs number of cells. (B) Percentage of NKG2D positive cells among NK cells alone (NK) 
or co-cultured with TAF (NK/TAF) in contact or separated by transwell (NK TW, NK TW/TAF). (c) IL-2-mediated upregulation of NKG2D mRNA was analyzed in 
NK cells alone (dark gray) or co-cultured with TAF (light gray), by quantitative real-time PCR at the indicated time points (0, 3, 6, and 12 h). Results are expressed as 
2−ΔΔCT and are representative of three independent experiments. (D) Transforming growth factor (TGF)β was measured by ELISA in the supernatant of TAF from six 
patients. Results are expressed as picogram per milliliter. (e) Reverse cytolysis (ATCC) of the target P815 cell line exerted by NK cells alone (NK) or co-cultured with 
TAF (NK/TAF), in the absence or presence of mAbs to the indicated NK cell surface molecules. Results are shown as percentage of 51Cr-specific release. (B,e) Mean 
with boxes and whiskers min to max of six experiments with NK cells derived from six distinct co-cultures with donor matched TAF. In each panel: ***p < 0.0001;  
ns, not significant.
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rituximab (anti-CD20 humanized antibody) did not stain TAF 
or FB in situ (Figures 4E,L,Q) and that cultured TAF or FB did 
not express FCγRI, FCγRII, and FCγRIII (Figure  3A, CD64, 
CD32, and CD16). Staining with only anti-human immuno-
globulin antiserum did not give any reactivity in CRC spacimens 
(Figures 4A,F,M).
Thus, we analyzed whether cetuximab can trigger the killing 
of CRC TAF or FB through the recognition of EGFR and the 
engagement of the CD16 receptor on NK  cells. We found that 
cetuximab can induce peripheral blood freshly isolated NK cells 
to exert ADCC of TAF (Figure 3B). This effect was dependent 
on the engagement of CD16 on NK cells as the covering of this 
receptor with a specific anti-CD16 mAb, but not that of CD56, 
strongly inhibit cetuximab-mediated ADCC of TAF (Figure 3C). 
Similar results were obtained using FB (not shown). NK  cells 
activated with IL-2 can also recognize and kill both TAF and FB, 
while freshly isolated NK cells exerted a very low cytotoxic effect 
(about 20%), in the absence of cetuximab, even at high E:T ratio 
(20:1, Figures 3D,E). The cytolytic function of activated NK cells 
was dependent on the interaction of LFA1, NKG2D, and DNAM1 
with their ligands, as specific antibodies to these molecules can 
inhibit TAF (Figure 3F) or FB (Figure 3G) lysis and the simul-
taneous covering of all these three NK cell receptors can abolish 
cell lysis (Figures 3F,G). These findings suggest that TAF can be 
AB C D E
F G
FigUre 3 | CRC-derived tumor-associated fibroblasts (TAF) can be targeted with cetuximab and killed by natural killer (NK) cells. (a) Mesenchymal stromal cells 
(MSC) from either CRC (TAF, upper row) or tumor free (FB, lower row) colon mucosa were assessed for the reactivity with cetuximab or rituximab (control 
isotype-matched antibody), as indicated, by indirect immunofluorescence with the specific Ab followed by AlexaFluor647 anti-human antiserum and FACS analysis. 
The expression on MSC of CD16 (FcγRIII), CD32 (FcγRII), and CD64 (FcγRI) antigens, upon immunofluorescence with specific mAbs followed by AlexaFluor647  
goat anti-mouse (GAM), is also shown. In each panel: negative control (anti-human antiserum or GAM alone, thin black line) and reactivity with the indicated 
antibody (thick black line). Numbers in each subpanel are the percentage above the bar and the mean fluorescence intensity (MFI, below the bar, a.u.) of positive 
cells. (B) Antibody-dependent cellular cytotoxicity (ADCC) of TAF by NK cells at the NK:TAF ratio of 5:1 was evaluated with cetuximab or rituximab (2 µg/ml).  
(c) Cetuximab-mediated ADCC of TAF in the presence of the anti-CD16 monoclonal antibody (mAb) or the control anti-CD56 mAb (2 µg/ml). (D,e) Cytolysis  
exerted by resting (black) or IL-2-activated (gray) NK cells at the indicated effector:target ratio (20:1, 10:1, 5:1) against TAF (D) or FB (e). (F,g) Effect of anti-NKG2D, 
anti-DNAM1, and anti-lymphocyte function associated (LFA)1 mAbs (2 µg/ml) on TAF (F) or FB (g) lysis exerted by IL-2-activated NK cells at 20:1 effector:target 
ratio. Results are shown as percentage of 51Cr-specific release and are the mean with boxes and whiskers min to max of six independent experiments with matched 
TAF and FB from six different patients. ***p < 0.0001; **p < 0.001.
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FigUre 4 | CRC tumor-associated fibroblasts express EGFR and are recognized by cetuximab at the tumor site. Reactivity of the humanized antibody cetuximab 
(B,c,g,h,n,O) was evaluated by immunohistochemistry on the CRC areas (OMCR-1a, upper row and OMCR-2, lower row) or the tumor free colon mucosa 
(OMCR-1b, middle row). Left panels (a,F,M): negative control (anti-human antiserum alone). Upper and central rows: reactivity on mesenchymal stromal cells (MSC) 
[panels (B,g) and arrows in panel (c,h)]. Lower row: reactivity on epithelial cells [panel (n) and arrows in panel (O)]. (c,h,O) Enlargements of the squares indicated 
in panels (B,g,n). MSC were identified by the specific expression of vimentin (D,i,P). (e,l,Q) Reactivity of the control antibody rituximab. Data are representative  
of specimens from carcinoma or tumor free mucosa of six different patients. Images were taken with the Leica microscope DM MB2 microscope equipped with a 
charged coupled device camera (Olympus DP70); images were taken at 200× and 400× magnification.
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recognized and lysed by activated, but not resting NK cells that, 
in turn, can be triggered to kill TAF by cetuximab.
crc lymphocyte infiltrate is enriched  
in nKp46+ nK cells: interaction With 
autologous TaF
To verify the possible interactions between NK cell and MSC at 
the tumor site, we obtained NK  cells or TAF from CRC cell 
suspensions and performed phenotypic analyses and co-culture 
experiments. In 45 CRC specimens, cell suspensions obtained 
from the tumor (K) or the non-tumor (N) areas, were cultured 
12 h in flat-bottom plates to remove adherent cells; then, non-
adherent cells were stained with anti-CD45 (leukocyte marker), 
anti-CD3 (T  cell marker), and anti-NKp46 (NK  cell marker) 
mAbs, followed by FACS analysis. As shown in Figure 5A, the 
mean percentage of NKp46+CD45+ cells was 0.93% in N or 
0.64% in K (Figure 5A, right graph, gated on R1 in the left dot 
plot). To determine with more precision the NK cell infiltrate, 
NKp46+CD3− cells were evaluated in the same K or N CRC 
samples, gated on CD45+ cells (gate R2 in Figure 5A): the mean 
percentage of NKp46+CD3− cells was 1.8%, with seven cases 
between 4 and 10%, in the tumor areas (K), and 0.87% in N areas 
(in all but two cases between 2.1 and 3.8%) (Figure  5B, right 
graph, gated on R3 in the left dot plot). We further characterized 
the NK cell population, in 20 cases (out of 45, due to the shortage 
of cells) for the expression of CD16 and CD56 in NKp46+CD3− 
cells with a four-color immune staining. Figure 5C shows a sig-
nificantly higher percentage of CD16+CD56+ NKp46+CD3− cells 
in the tumor (K) vs non-tumor (N) areas (mean value: 14.6 vs 
4.9%). In Figure 5D, the two cases indicated with black squares 
in Figures 5B,C are shown, as examples of NK cell populations 
enriched or not in CD16+CD56+ (OMCR16-030 and OMCR16-
001, respectively) cells in the tumor (K). In particular, OMCR16-
030 specimen showed 42.5% (17.5% double positive and 25% 
single positive) CD16+ cells, while in OMCR16-001 sample 
CD16+ cells were 6.6% (3.8% double positive and 2.8% single 
positive).
Then, NKp46+CD3− cells were sorted from five CRC (K), 
including OMCR16-030 and OMCR16-001, according to the 
protocol shown in Figure S4 in Supplementary Material. Sorted 
NKp46+CD3− cells (98.5% purity) were expanded with IL-2 
and used in ATCC against P815 (E:T ratio 2.5:1), in crystal 
violet assay with autologous TAF or in cytotoxicity assay (E:T 
ratio 10:1) against Caco2 or HCT15 CRC cell lines. These cell 
populations expressed CD16, NKG2D, DNAM1, and NKp46 
(Figure 6A). As shown in Figure 6B, NKp46+CD3− cells derived 
from four out of five CRC specimens could be elicited to activate 
ATCC via CD16, NKp46, DNAM1, and NKG2D (the anti-CD3 
mAb used as negative control did not increase the spontaneous 
activity, identified as CTR in the figure), indicating that this 
cell population is potentially cytotoxic. Three cases (Figure  6, 
OMCR16-030, black circles and column; OMCR16-082, gray 
circles and column; and OMCR16-001, white circles and column) 
were studied in more detail as autologous TAF have been derived. 
OMCR16-030 and OMCR16-082 NKp46+CD3− cells could kill 
most autologous TAF; by contrast, NKp46+CD3− cells derived 
from OMCR16-001 population were not effective (Figure 6C). To 
explain this different behavior, we tested all the NKp46+CD3− cell 
populations for the expression of some HLA-class I inhibitory 
receptors, such as KIR2D and NKG2A (5, 22, 37). We found a 
higher percentage of cells expressing the inhibitory molecule 
AB
C D
FigUre 5 | CRC cell suspensions contain infiltrating NKp46+ CD16+ natural killer (NK) cells. (a,B) CRC cell suspensions obtained from the tumor (K) or the 
non-tumor (N) areas of 45 specimens were stained with the anti-CD45 T205, the anti-CD3 JT3A, followed by FITC-anti IgM and APC-anti-IgG2a goat anti-mouse 
antiserum and PE-anti-NKp46 monoclonal antibodies (mAbs), and analyzed by FACS. Panel (a), left: dot plot of immunofluorescence of a representative case of 
CRC. R1: gate on NKp46+CD45+cells, R2: gate on CD45+ cells. Panel (a), right: percentage of NKp46+CD45+ cells in gate as R1 in 45 CRC. ***p < 0.001, 
non-parametric two-tailed t test Mann–Whitney. Panel (B), left: dot plot of immunofluorescence on gate R2 of the sample depicted in panel (a). R3: gate on 
NKp46+CD3− cells. Panel (B), right: percentage of NKp46+CD3− cells in gate R3 in 45 CRC. The two cases indicated with black squares (OMCR16-030, above the 
mean and OMCR16-001, below the mean) are shown in more detail in panel (D). Dark gray squares indicate the six cases, besides OMCR16-030, with 
NKp46+CD3− cells between 4 and 10%, (c) CRC cell suspensions obtained from the tumor (K) or the non-tumor (N) areas of 20 specimens were stained with the 
PE/Dazzle-anti-CD3, PE-Cy7-anti-NKp46, PE-Cy5-anti-CD56, and Pacific Blue-anti-CD16 mAbs. CD56+CD16+ cells among the NKp46+CD3− cell population. 
***p < 0.001, non parametric two-tailed t test Mann–Whitney. Black squares: OMCR16-030 and OMCR16-001. (D) CD56 and CD16 expression (right dot plots) on 
the NKp46+CD3− tumor cell population (K, gated in R1, left dot plots) of the two cases indicated with black squares in panels (B,c) (OMCR16-030 and OMCR16-
001). In each quadrant: percentage of positive cells.
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NKG2A among the NKp46+CD3− population derived from 
OMCR16-001 CRC, compared to the same population sorted 
from OMCR16-030 and OMCR16-082 CRC (Figure  6D). 
Moreover, the MFI ratio vs the negative control (measure of 
the intensity of NKG2A expression) was more than twofold 
or threefold in OMCR16-001 NKp46+CD3− cells. As NKG2A 
inhibitory signal is elicited by binding to HLA-I, we analyzed 
the ability of the different NKp46+CD3− cell populations to lyse 
HLA-I+ (Caco2) or HLA-I− (HCT15) CRC cell lines. As shown in 
Figure 6E, NKp46+CD3− cells from OMCR16-001 case did not 
kill Caco2 (Figure 6E, upper graph, white circles) but was able to 
lyse HCT15 (Figure 6E, lower graph, white circles), at variance 
A B
C D E
FigUre 6 | Sorted NKp46+ CD3− cells from CRC give rise to natural killer (NK) cells with anti-tumor-associated fibroblasts (TAF) and antitumor activity.  
(a) Phenotype of cell suspensions from five CRC, by immunofluorescence with monoclonal antibodies (mAbs) against the indicated molecules (CD16, CD56, 
NKp46, DNAM1, and NKG2D) followed by anti-isotype APC-goat anti-mouse (GAM) antiserum and FACS analysis. Results are expressed as percentage of  
positive cells. Mean ± SEM of the five cases is shown. (B) Sorted NKp46+ CD3− cells of 5 CRC, expanded with IL-2, were assayed in redirected killing (ATCC) 
against P815, in a 51Cr release assay, using mAbs recognizing CD16, NKp46, DNAM1, and NKG2D (CD3 was used as negative control). Results are expressed as 
percentage of P815 cell lysis. Mean ± SEM of the five cases is shown. (c) NKp46+ CD3− cell populations from three CRC [OMCR16-030, OMCR16-082, and 
OMCR16-001, black, gray, and white, respectively, as the circles in panels (a,B)] were co-cultured for 24 h with autologous TAF at the ratio of 10:1 (NKp46+CD3−/
TAF); then TAF viability was assessed by crystal violet assay and results expressed as percentage of dead cells. Mean ± SEM of triplicate samples is shown.  
(D) Expression of NKG2A by indirect immunofluorescence with the specific mAb (gray histograms), followed by isotype-specific APC-GAM and FACS analysis,  
on OMCR16-001, OMCR16-030, and OMCR16-082 NKp46+CD3− cells. White histograms: negative control with APC-GAM alone. Results are expressed as  
log far-red fluorescence intensity (a.u.) vs number of cells. In each quadrant: percentage of positive cells and MFI ratio (MFI gray/MFI white histograms, a.u.).  
(e) Cytolytic activity of NKp46+CD3− cell populations from OMCR16-030, OMCR16-082, and OMCR16-001 (black, gray, and white circles, respectively) against  
the HLA-I+ Caco2 (upper graph) or the HLA-I− HCT15 (lower graph) CRC cell lines, in a 51Cr release assay. Results are expressed as percentage of specific 
cytolysis. Mean ± SEM of the three cases is shown.
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with OMCR16-030 and OMCR16-082 NKp46+CD3− cells that 
efficiently killed both CRC cell lines (Figure 6E, upper graph vs 
lower graph, gray and black circles).
DiscUssiOn
Here, we show that TAF from CRC reduce the NKG2D expres-
sion levels, through a direct cell-to-cell contact, and impair the 
NKG2D-mediated triggering of tumor cell lysis, sparing ADCC. 
Of note, the anti-EGFR therapeutic antibody cetuximab can 
overcome NK  cell impairment, triggering the CD16-mediated 
ADCC of MSC.
In the tissue microenvironment, lymphocytes can be localized 
in contact with TAF, besides carcinoma cells, thus making pos-
sible that a negative signal impairs NK cell-mediated antitumor 
immune response in vivo (38–41). We found in the tumor a lym-
phoid infiltrate containing NKp46+CD3− NK cells, according to 
other reports (42, 43). This population is enriched, in the tumor 
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areas, in CD16+ cells, suggesting that ADCC can be elicited by 
humanized Ab-based therapy.
Along this line, NK cell isolated from the tumor and cultured 
with IL-2, could still be triggered via CD16, besides through 
the engagement of other NK cell activating receptors, including 
NKG2D. It is of note that sorted NKp46+CD3− cells were able 
to kill autologous TAF; in  vivo, this might represent a control 
mechanism to reduce TAF-mediated regulatory effect on NK cell 
function. In turn, the downregulation of NKG2D activation 
would be a mechanism to control NK cell-mediated recognition 
of MSC; this mechanism would limit the damage of NK cells to 
healthy FB. More importantly, the finding that resting peripheral 
blood NK cells can be triggered to kill MSC by cetuximab sug-
gests an additional potential therapeutic effect of the humanized 
Ab to restore a full cytotoxic response against CRC (44–46). 
On the other hand, the effect of cetuximab administration in 
CRC patients might result in a lower therapeutic effect on the 
primary tumor due to the presence in situ, as we have shown by 
immunochemistry, of TAF that express EGFR and can subtract 
the antibody, thus reducing its availability (44–46). Cetuximab 
would be more efficacious in the metastatic tumor, where cancer 
cells are no longer protected by colon MSC. Nevertheless, we 
demonstrated that cetuximab is able to trigger NK cell-mediated 
ADCC, either against tumor cells or against TAF, thus potentially 
overcoming MSC-mediated immunosuppression.
We have also highlighted that both MSC and CRC cells are 
recognized by NK lymphocytes through the same receptors, 
namely LFA1, NKG2D, and DNAM1. This share of receptor 
molecules can have a role in favoring the escape of tumor cells 
from NK cell mediated killing. Indeed, in the tumor NK cells can 
bind to either CRC cells or MSC, instead of targeting primarily 
tumor cells and this can divert the antitumor immune response. 
At variance with our data, it has been shown that NCR, besides 
NKG2D and DNAM1 (47), are involved in the killing of CRC 
cells (48); however, in this report cancer initiating cells, but not 
the unselected tumor cell populations, were lysed through NCR. 
In addition, other authors described that reactivity with Fc-NCR 
becomes evident only when CRC cell lines are infected with 
parvovirus (49). Thus, our findings that the Fc-NCR chimeras 
do not react with the CRC cell lines analyzed, would suggest that 
different surface molecules are involved in the killing of cancer 
stem cells or virus-infected cells, compared to the large majority 
of tumor cells.
We noted that MSC from both carcinoma (TAF) and tumor free 
colon mucosa (FB) showed a similar behavior suggesting that the 
ability of inhibiting lymphocyte-mediated activities is an intrinsic 
and basic feature of MSC. A limitation to this interpretation of our 
results is represented by the fact that, to achieve a stock of cells for 
functional experiments, MSC were seeded in vitro and expanded 
in culture (4, 29, 31), leading to the loss of features, character-
izing TAF or FB, present in situ. It has been reported that TAF 
from melanoma lesions can inhibit NK cell activation better than 
skin FB isolated from healthy donors (20); this inhibiting effect is 
reported to depend on the production of PGE2 during NK-TAF 
interaction. Our results indicate that TAF from CRC, matched 
with FB from the tumor free mucosa of the same patient, do not 
show different phenotypic or functional characteristics. However, 
in our study also FB come from a tissue potentially subjected to 
inflammatory factors released in the tumor and in the surround-
ing microenvironment, so that they might be considered not 
entirely healthy cells. These discrepancies could also be related 
to the use, in the cited report, of unmatched skin FB. Indeed, 
NK cells are sensitive to the inhibitory signal delivered by HLA-I 
(50, 51). Thus, the effect of FB from different donors on the same 
NK cell population, and vice versa, may depend on the fact that 
this population bear inhibiting HLA-I receptors at the cell surface 
that recognize different HLA-I alleles on FB. In support to this, we 
found that tumor-derived NK cells expressing high levels of the 
inhibitory receptor NKG2A did not aggress autologous TAF nor 
HLA-I+ CRC cells. In addition, we did not identify PGE2 as one of 
the factors responsible for inhibiting signals delivered to NK cells; 
rather, TGFβ released by MSC seems to be the factor potentially 
implied. This would suggest that the molecular mechanism 
underlying stromal-mediated inhibition is not the same for dif-
ferent tissue districts. According to our data, it has been reported 
that TGFβ can impair the IL-2-mediated upregulation of NKG2D 
mRNA (52–54). Furthermore, as demonstrated by experiments 
with millicell transwell chambers, the downregulation of NKG2D 
on NK cells was not detected when NK cells and MSC were not 
in direct contact and only soluble molecules present in co-culture 
supernatant could bind to NK cells. Thus, the reduced NKG2D 
surface expression and function is likely due to the effect of TGFβ 
rather than to soluble ligands which cover NKG2D molecule, 
affecting antibody reactivity (55).
In conclusion, our findings support that MSC may be a target 
for immunotherapies designed to favor antitumor lymphocyte 
effector functions (9); the use of cetuximab in anti-CRC thera-
peutic schemes should be useful to overcome MSC-mediated 
immunosuppression.
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FigUre s1 | Phenotype of cultured MSC isolated from colon carcinoma 
[tumor-associated fibroblasts (TAF)] and healthy mucosa (FB). MSC were isolated 
from colon carcinoma mucosa (TAF) and from tumor free mucosa (FB) of the 
same patient, cultured and analyzed for the expression of the indicated surface 
(CD73, CD90, CD105, and CD146) and cytoplasmic (collagen and vimentin) 
markers (a,c) or the NKG2D ligands or DNAM1 ligands [MICA, ULBP3, and 
poliovirus receptor (PVR)], intercellular adhesion molecule 1, or the Fc-NKG2D 
and the Fc-DNAM1 chimeras (B,D) by indirect immunofluorescence and FACS 
analysis. (a,B) One representative experiment: TAF or FB were stained with the 
monoclonal antibodies to the indicated molecules followed by AlexaFluor647-
conjugated anti-isotype specific goat anti-mouse (gray histograms) or with the 
second reagent alone (negative control, white histogram). In each subpanel, the 
percentage of positive cells, above the bar set on the negative control, and the 
mean fluorescence intensity (MFI, below the bar) are indicated. Results are 
shown as Log far-red fluorescence intensity (arbitrary units, a.u.) vs cell number. 
(c,D) Results are expressed as percentage of positive cells and are the mean 
with boxes and whiskers min to max of six independent experiments with 
matched TAF (white boxes) and FB (gray boxes) from six different patients.
FigUre s2 | Expression of intercellular adhesion molecule (ICAM)1, NKG2D 
ligands (NKG2D-L) or DNAM1 ligands (DNAM1-L) on CRC cell lines. The 
carcinoma cell lines Caco2, HT29, HCT15, SW480, DLD1, HCT116, LS180  
(a), WiDr, LoVo, Colo205, Colo320 DMF, SW620, T84, and SW480 (B) were 
analyzed for the expression of ICAM1, with the specific monoclonal antibodies, 
or NKG2D-L or DNAM1-L with the Fc-NKG2D or Fc-DNAM1 chimeric molecules 
by immunofluorescence assay and FACS analysis. In each panel, the negative 
control (AlexaFluor647 goat anti-mouse for ICAM1 and AlexaFluor647 human 
antiserum for the chimeras, black histograms) vs positive samples (gray 
histograms) is shown. Data are expressed as Log far-red fluorescence intensity 
(arbitrary units, a.u.) vs number of cells.
FigUre s3 | Expression of MICA, ULBPs, or poliovirus receptor (PVR) on 
selected CRC cell lines. The carcinoma cell lines Caco2, HCT15, and SW480 
were analyzed for the expression of MICA, ULBP1, ULBP2, ULBP3, and PVR  
with specific monoclonal antibodies by immunofluorescence assay and FACS 
analysis. In each panel, the negative control (AlexaFluor647 goat anti-mouse, white 
histograms) vs positive samples (gray histograms) is shown. Data are expressed 
as Log far-red fluorescence intensity (arbitrary units, a.u.) vs number of cells.
FigUre s4 | Sorting strategy for NKp46+CD3− cells from CRC. NKP46+CD3− cell 
sorting from the OMCR16-030 CRC is shown as an example. Representative 
gating strategy: plots show first the recognition of the population of interest, without 
doublets, than the target of sorting NKp46+cells on CD3−. (a) Gray dots are 
doublet 1 and 2 events [depicted in panels (B,c)] excluded on the basis of physical 
parameters; (D) dark gray dots are cells excluded on the basis of CD3 expression. 
(e) Gray dots are sorted NKp46+CD3− cells. (F) CD16 and NKp46 expression 
(NKP46 PE-Cy7 vs CD16 Pacific Blue) on CD3− cells sorted in panel (e).
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